by Rosa Castro | Jun 30, 2022 | #A2Medicines, Monkeypox, The View from EPHA, Universal Access and Affordable Medicines | Latest Developments
“With HERA up and running, the EU has significantly reinforced its capacity to respond and address new health threats decisively”. This is what Health Commissioner Stella Kyriakides said on 28 June 2022 when she announced that the first batch of monkeypox vaccines...
by European Public Health Alliance | Dec 13, 2021 | Universal Access and Affordable Medicines | Latest Developments
As the past 2 years have been dominated by COVID-19, the upcoming revision of the EU pharmaceutical legislation could not come at a more critical time. The pandemic increased the relevance and power of the pharmaceutical industry as a key provider of vaccines and...
by European Public Health Alliance | Sep 17, 2021 | Universal Access and Affordable Medicines | Latest Developments
On 16 September 2021, Dr Milka Sokolović, Director General of EPHA gave a speech at the 71st session of the WHO Regional Committee for Europe where she emphasized the need for better access to effective, novel, high-priced medicines and how the Oslo Medicines...
by European Public Health Alliance | Sep 13, 2021 | Universal Access and Affordable Medicines | Latest Developments
The COVID-19 pandemic has highlighted the importance of addressing shortages of critical medicines and coordinating clinical trials for the development of new medicines. It has also shown how a lack of transparency on clinical trials threatens to delay the development...
by European Public Health Alliance | Sep 5, 2021 | Universal Access and Affordable Medicines | Latest Developments
Ahead of the publication of the European Commission’s proposal for an operational Health Emergency Preparedness and Response Authority (HERA), to ensure better EU preparedness and response to serious cross border health threats, the European Public Health...
by EPHA | May 21, 2021 | Universal Access and Affordable Medicines | Latest Developments
“When my son was diagnosed with cancer, he was treated with old, off-label drugs. The same happened two years later when he relapsed two years later, despite a poor prognosis. Not a single experimental drug was on trial to give us hope. We have to change this...
